Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1989 1
1991 1
1992 2
1998 1
1999 1
2000 1
2002 2
2003 1
2004 1
2006 1
2008 3
2009 2
2011 2
2012 2
2015 4
2016 2
2017 1
2018 2
2019 4
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. Pi-Sunyer X, et al. N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892. N Engl J Med. 2015. PMID: 26132939 Free article. Clinical Trial.
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skjøth TV, Manning LS, Pi-Sunyer X; SCALE Obesity Prediabetes NN8022-1839 Study Group. le Roux CW, et al. Lancet. 2017 Apr 8;389(10077):1399-1409. doi: 10.1016/S0140-6736(17)30069-7. Epub 2017 Feb 23. Lancet. 2017. PMID: 28237263 Free article. Clinical Trial.
Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C; PIONEER 5 Investigators. Mosenzon O, et al. Lancet Diabetes Endocrinol. 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. Lancet Diabetes Endocrinol. 2019. PMID: 31189517 Free article. Clinical Trial.
Thyrotoxic hepatitis.
Barzilay-Yoseph L, Shabun A, Shilo L, Hadary R, Nabriski D, Kitay-Cohen Y. Barzilay-Yoseph L, et al. Among authors: nabriski d. Isr Med Assoc J. 2011 Jul;13(7):448-50. Isr Med Assoc J. 2011. PMID: 21838194 Free article. No abstract available.
Medical therapy for obesity: present and future.
Ness-Abramof R, Nabriski D, Apovian CM. Ness-Abramof R, et al. Among authors: nabriski d. Isr Med Assoc J. 2004 Dec;6(12):760-5. Isr Med Assoc J. 2004. PMID: 15609891 Free article. Review.
Orthopedic-Metabolic Collaborative Management for Osteoporotic Hip Fracture.
Rotman-Pikielny P, Frankel M, Lebanon OT, Yaacobi E, Tamar M, Netzer D, Nabriski D, Nyska M, Brin YS. Rotman-Pikielny P, et al. Among authors: nabriski d. Endocr Pract. 2018 Aug;24(8):718-725. doi: 10.4158/EP-2018-0082. Epub 2018 Aug 7. Endocr Pract. 2018. PMID: 30084682
Basal insulin and cardiovascular and other outcomes in dysglycemia.
ORIGIN Trial Investigators; Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. ORIGIN Trial Investigators, et al. N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11. N Engl J Med. 2012. PMID: 22686416 Free article. Clinical Trial.
32 results